| Literature DB >> 18772641 |
Michael E Farkouh1, Freek W A Verheugt, Sean Ruland, Howard Kirshner, Raban Jeger, Xavier Gitton, Gerhard Krammer, Kirstin Stricker, Peter Sallstig, Bernhard Mellein, Patrice Matchaba, James H Chesebro.
Abstract
The 52-week Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) investigated the gastrointestinal and cardiovascular safety profile of lumiracoxib 400 mg once daily compared with 2 traditional nonsteroidal anti-inflammatory drugs (NSAIDs): ibuprofen 800 mg 3 times daily and naproxen 500 mg twice daily. Data from TARGET were analyzed to examine the effect of lumiracoxib compared with ibuprofen and naproxen on blood pressure (BP), incidence of de novo and aggravated hypertension, prespecified edema events, and congestive heart failure. Lumiracoxib resulted in smaller changes in BP as early as week 4. Least-squares mean change from baseline at week 4 for systolic BP was +0.57 mm Hg with lumiracoxib compared with +3.14 mm Hg with ibuprofen (P<.0001) and +0.43 with lumiracoxib compared with +1.80 mm Hg with naproxen (P<.0001). In conclusion, the use of lumiracoxib and traditional NSAIDs results in differing BP changes; these might be of clinical relevance.Entities:
Mesh：
Substances：
Year: 2008 PMID： 18772641 PMCID： PMC8109916 DOI： 10.1111/j.1751-7176.2008.07802.x
Source DB: PubMed Journal: J Clin Hypertens (Greenwich) ISSN： 1524-6175 Impact factor: 3.738